Featured Research

from universities, journals, and other organizations

New marker of drug response may speed pace of lung cancer prevention trials

Date:
January 8, 2013
Source:
University of Colorado Denver
Summary:
Testing medicines to prevent lung cancer requires treating many thousands of high-risk individuals and then waiting five, 10 or 15 years to discover which of them develop cancer and which, if any, experience survival benefit from the treatment. A new study proposes a possible point on the way to benefit, which if validated, could dramatically reduce the number of patients needed and time required to test drugs for lung cancer prevention.

Testing medicines to prevent lung cancer requires treating many thousands of high-risk individuals and then waiting 5, 10 or 15 years to discover which of them develop cancer and which, if any, experience survival benefit from the treatment. A University of Colorado Cancer Center study recently published in the journal Cancer Prevention Research proposes a possible waypoint on the way to benefit, which if validated, could dramatically reduce the number of patients needed and time required to test drugs for lung cancer prevention.

Related Articles


"Chemoprevention is an important approach that has been way behind in terms of scientific advances for lung cancer," says Fred R. Hirsch, MD, PhD, investigator at the CU Cancer Center and professor of medical oncology and pathology at the CU School of Medicine. "If we could find a surrogate endpoint for lung cancer mortality -- an intermediate endpoint -- it would make it much easier to conduct smaller trials in much shorter time."

The original intent of the study was to discover certain microRNAs whose level of expression might predict patients likely to respond to the possible chemopreventive drug, Iloprost. If an especially high or low microRNA expression predicted response, it would allow researchers to test the drug only in the population most likely to benefit. Unfortunately, while levels of seven miRNAs were found to be correlated with the appearance of lung cancer, none predicted response to the drug.

It might have been a dead-end study if it weren't for microRNA-34c.

To a striking degree, changes in the expression of this molecule six months after treatment correlated with benefit from the drug seen much later. In those who later showed benefit, microRNA-34c expression was down six months after treatment; in patients who showed no benefit, microRNA-34c expression remained unchanged.

"Instead of waiting for an endpoint 15 years in the future, we could potentially discover the effectiveness of chemopreventive agents only six months after treatment. It would speed up the pace of discovery and eventually bring new chemopreventive agents much faster to the market," Hirsch says.

Hirsch cautions that his discovery, with CU Cancer Center colleagues including Celine Mascaux, MD, PhD, of this potential intermediate endpoint is just that: potential. Further work is needed to validate the predictive power of miRNA-34c in showing chemopreventive response. But Hirsch and colleagues are hopeful not only that miRNA-34c could be this predictive waypoint, but that the cutting edge technique of looking beneath genes, beneath even RNA and mRNA into the molecular world of microRNA will help them discover the roots of the disease.

"The approach is new and it needs to be further explored," Hirsch says.


Story Source:

The above story is based on materials provided by University of Colorado Denver. The original article was written by Garth Sundem. Note: Materials may be edited for content and length.


Journal Reference:

  1. C. Mascaux, W. J. Feser, M. T. Lewis, A. E. Baron, C. D. Coldren, D. T. Merrick, T. C. Kennedy, J. I. Eckelberger, L. M. Rozeboom, W. A. Franklin, J. D. Minna, P. A. Bunn, Y. E. Miller, R. L. Keith, F. R. Hirsch. Endobronchial miRNAs as biomarkers in lung cancer chemoprevention. Cancer Prevention Research, 2012; DOI: 10.1158/1940-6207.CAPR-12-0382

Cite This Page:

University of Colorado Denver. "New marker of drug response may speed pace of lung cancer prevention trials." ScienceDaily. ScienceDaily, 8 January 2013. <www.sciencedaily.com/releases/2013/01/130108142128.htm>.
University of Colorado Denver. (2013, January 8). New marker of drug response may speed pace of lung cancer prevention trials. ScienceDaily. Retrieved April 2, 2015 from www.sciencedaily.com/releases/2013/01/130108142128.htm
University of Colorado Denver. "New marker of drug response may speed pace of lung cancer prevention trials." ScienceDaily. www.sciencedaily.com/releases/2013/01/130108142128.htm (accessed April 2, 2015).

Share This


More From ScienceDaily



More Health & Medicine News

Thursday, April 2, 2015

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Wound-Healing Laser Soon to Be a Reality Israeli Scientist

Wound-Healing Laser Soon to Be a Reality Israeli Scientist

Reuters - Innovations Video Online (Apr. 1, 2015) Israeli scientists says laser bonding of tissue allows much faster healing and less scarring. Amy Pollock has more. Video provided by Reuters
Powered by NewsLook.com
Liberia Sees Resurgence of Drug Trafficking as Ebola Wanes

Liberia Sees Resurgence of Drug Trafficking as Ebola Wanes

AFP (Apr. 1, 2015) The governments of Liberia and Sierra Leone have been busy fighting the menace created by the deadly Ebola virus, but illicit drug lords have taken advantage of the situation to advance the drug trade. Duration: 01:12 Video provided by AFP
Powered by NewsLook.com
Stigma Stalks India's Leprosy Sufferers as Disease Returns

Stigma Stalks India's Leprosy Sufferers as Disease Returns

AFP (Apr. 1, 2015) The Indian government declared victory over leprosy in 2005, but the disease is making a comeback in some parts of the country, with more than a hundred thousand lepers still living in colonies, shunned from society. Duration: 02:41 Video provided by AFP
Powered by NewsLook.com
7-Year-Old Girl Gets 3-D Printed 'robohand'

7-Year-Old Girl Gets 3-D Printed 'robohand'

AP (Mar. 31, 2015) Although she never had much interest in prosthetic limbs before, Faith Lennox couldn&apos;t wait to slip on her new robohand. The 7-year-old, who lost part of her left arm when she was a baby, grabbed it as soon as it came off a 3-D printer. (March 31) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins